Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer Japan and Astellas Pharma have agreed to terminate the distribution and co-promotion agreement for Caduet combination tablets, a combination drug of hypertension and hypercholesterolemia, in Japan on 31 March 2015.
Subscribe to our email newsletter
Caduet Combination Tablets is an oral combination drug of hypertension treatment Norbasc Tablets sold by Pfizer, and Lipitor Tablets co-promoted by Pfizer and Astellas.
As part of the agreement, promotion of Caduet, which to date has been carried out jointly by the two companies, will be conducted solely by Pfizer from 1 October 2014.
Until the termination of the agreement, Astellas will continue its distribution, while the distribution will be transferred to Pfizer on 01 April 2015.
The two firms will continue to co-promote hypercholesterolemia and familial hypercholesterolemia treatment Lipitor Tablets.
The two firms have concluded a co-promotion agreement in August 2009 for Caduet Combination Tablets and have been carrying out co-promotion activity since the product’s launch in December of the same year.